Neil Bodick - Flexion Therapeutics Insider

FLXN -- USA Stock  

USD 18.74  0.88  4.49%

Dr. Neil Bodick, M.D., Ph.D. serves as Chief Scientific Officer of the Company. He was Chief Medical Officer of Flexion Therapeutics, Inc. Previously, Dr. Bodick was at Eli Lilly and Company, where he founded Chorus and served as Chief Medical Officer and Chief Operating Officer. Prior to that, Dr. Bodick was responsible for earlyphase clinical investigation at Lilly Research Laboratories. He also was Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the development of computerbased systems to support imageintensive diagnosis. Dr. Bodick holds 13 patents in the areas of neuroscience and computer science and is the recipient of the Biomedical Research Service Award and the New Investigator Research Award from the National Institutes of Health.
Age: 70  Founder Since 2017      

Neil Bodick Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (27.0) % which means that it has lost $27.0 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (87.51) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 159.16 M in liabilities with Debt to Equity (D/E) ratio of 85.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Flexion Therapeutics has Current Ratio of 12.64 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is headquartered in Burlington, Massachusetts. Flexion Therapeutics operates under Drug Manufacturers - Specialty Generic classification in USA and traded on BATS Exchange. It employs 268 people.Flexion Therapeutics (FLXN) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 268 people. Flexion Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Flexion Therapeutics Leadership Team

David Arkowitz, CFO, Principal Financial Officer and Principal Accounting Officer
Sandesh Mahatme, Director
Scott Canute, Director
Mark Levine, Senior Vice President General Counsel, Secretary
Kerry Wentworth, Chief Regulatory Officer
Dan Thornton, Vice President - Market Access
John Magee, Vice President - Sales
Neil Bodick, Chief Medical Officer & Co-Founder
Mark Fraga, Vice President - Marketing
Michael Clayman, CEO, Co-Founder, Board Member
Ann Merrifield, Director
Alan Milinazzo, Independent Director
Jon Mahlowitz, VP of Legal Affairs
Frederick Driscoll, CFO and Principal Accounting Officer
Heath Lukatch, Independent Director
Patrick Mahaffy, Chairman of the Board
Samuel Colella, Independent Director
Yamo Deniz, Chief Medical Officer
Mark Stejbach, Director
Scott Kelley, Vice President - Medical Affairs

Stock Performance Indicators

Did you try this?

Run World Markets Correlation Now


World Markets Correlation

Find global opportunities by holding instruments from different markets
All  Next Launch World Markets Correlation

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally see Investing Opportunities. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.